CRBP Corbus Pharma

$-0.15 (-2.01%)

CRBP Stock Analysis Overview

What this means: Corbus Pharma (CRBP) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 86 means that our comprehensive methodology rates Corbus Pharma above 86% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full CRBP report

Corbus Pharma (CRBP) Analyst Forecast

Next 12 months ➝Current Price$7.3152-week High$8.6652-week Low$3.29MEAN$20.25+177.02%HIGH$28.00+283.04%LOW$12.00+64.16%
  • Last Price$7.31
  • Previous Close$7.46
  • Change $-0.15
  • Open$7.40
  • Volume941,459
  • Avg. Volume (100-day)1,028,443
  • Market Capitalization$530M
  • Days Range $7.22 - $7.55
  • 52-week Range $3.29 - $8.66
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-1.13
  • Earnings Date08/13/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta0.673
  • PEG Ratio
  • Volatility0.63
  • Average True Range0.08
Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.